<SEC-DOCUMENT>0001193125-11-122961.txt : 20110503
<SEC-HEADER>0001193125-11-122961.hdr.sgml : 20110503
<ACCEPTANCE-DATETIME>20110503084529
ACCESSION NUMBER:		0001193125-11-122961
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110502
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110503
DATE AS OF CHANGE:		20110503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		11802980

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): May&nbsp;3, 2011 (May 2, 2011) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200,
Broomfield, CO 80021 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not
Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item 1.01 Entry into a Material Definitive Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;2, 2011, (the &#147;effective date&#148;) ARCA biopharma, Inc. (&#147;ARCA&#148;) entered into an agreement (the
&#147;Agreement&#148;) with Novartis International Pharmaceutical Limited (&#147;Novartis&#148;) under which ARCA has assigned its patent rights related to an undisclosed molecular target. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Agreement, ARCA will receive an upfront payment of $2.0 million from Novartis. Under the Agreement, ARCA is also
eligible to receive payments totaling $17.5 million upon the achievement of certain clinical, regulatory and commercial milestones. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A press release is attached as Exhibit&nbsp;99.1 hereto, the contents of which are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma signs global rights agreement with large pharma company for one of ARCA&#146;s early stage assets,&#148; dated May&nbsp;3,
2011.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;3, 2011 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: Senior Vice President and General Counsel</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma signs global rights agreement with large pharma company for one of ARCA&#146;s early stage assets,&#148; dated May&nbsp;3,
2011.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g181340g10a34.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA SIGNS GLOBAL RIGHTS
AGREEMENT WITH LARGE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PHARMA COMPANY FOR ONE OF ARCA&#146;S EARLY STAGE ASSETS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, May&nbsp;3, 2011</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies
for cardiovascular diseases, today announced that it has entered into an agreement with Novartis pursuant to which Novartis is acquiring global patent rights to an undisclosed molecular target. ARCA will receive an upfront payment of $2.0 million
and is eligible to receive clinical, regulatory and commercial milestones totaling $17.5 million. Additional terms of the transaction were not disclosed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA is also currently seeking or evaluating business development opportunities for multiple additional compounds in various stages of development which are outside the Company&#146;s core focus area of
cardiovascular disease. These business development efforts do not include ARCA&#146;s lead compound,
Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), which is being
developed for cardiovascular disease and for which the Company is seeking strategic partners. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker being developed for atrial fibrillation and heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential
to be the first genetically-targeted atrial fibrillation prevention and/or heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148;
for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to
Gencaro and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention and/or heart failure treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual
results and performance could differ materially from those projected in the forward-looking statements as a </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">result of many factors, including, without limitation, the risks and uncertainties associated with: the
Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including
without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2010 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g181340g10a34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g181340g10a34.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3@#:`P$1``(1`0,1`?_$`+P```$$`@,!`0``````
M``````@`!PD*!`8!`@4#"P$!``$$`P$!``````````````<%!@@)`0(#!`H0
M```&`0($`P8$!`,%"0````$"`P0%!@<`$2$2$P@Q40E!T2*B%!5A<3(6\(&1
M(\%""J%B)#47L5*2,S0EE288$0`!`P($`P4#!0T)`````````0(#$00A$@4&
M,4$'46$B$PAQ@3*1L>$C%/"AP5*2LC-#<R2T-@G18G+31&05=C?_V@`,`P$`
M`A$#$0`_`+T.7,P5/#%;/9K:Z.5`ZA6L9&-$^O)S,@<!$C)@CS``F``YE%#;
M)I$XF'45]6NL6R^C6VY-Q[NFR1-1<D:*B/E=R1M?[%*YH&W-5W-?ML-+1,_%
MRKP1"-B=]0C*$F_4"I5"IPK`#J"W1F4Y";?*(`(<AG*K:0BFY%=O8F4Y?QUJ
MUW9_4EZBW.HK)L?2M.M]%>ZD2W<,TLCDY5R30IBG<3?:='=)MH:ZO)<+)3%6
M.:U,W9BQV''F)+O9[A3F+S1&/^10I52;5^8W%,X;DW_^R#N.VO@;Z^/4?+;H
M^"SV[YJ_[.YI_&GK;],-E/>K99+Q*=DC/\HR77>=W$-N0IHJ@BH9HV<[&KDR
M0-G"1%.`C9./$W#7WZKZZ?4II[62?8MN^7+;QO96SN<5<B*O^MX8_2=(>F6R
MGMF5TEY5BT3ZQGW_`*H\A?OMSU'KI_5PM"53`I#JI$@I=$R@&#<"IK#8C@4=
MO'X1U3I_Z@O7W3)J:E:;>5C:*YK;2X1U/?>+\Q]<72+:EU)Y=O)=T5B+59&<
M53']6%3@CO0K^4Y5K4K3'-Z?;7AA2C>5P=Q!S;CD`X-6;ER5!PQ?"`"!4E@^
M,0V*81X:S']/WK>V=U:O[;:^O0_8=SS-7Q8MA<Y*)E1'55%6N'B7@1WO#IAJ
M.VX77T#EEL6NIRS(F..&"\.[V!K$<F,4!'E`?BY@V,`@(#L)>(@.X>`_CK.=
MR/A1?,Q\6%/Q5X>^A%*.5&+*_"-,#OUS^1?Z#[]<G80+'\B_[??H!KLDYNQC
MA[]E$R9=Z_35<BW:(QO2`FUEVP6.\SH+#$U^/*1%8PNGG0-\9N5$G`#'`3%`
M0'/(NH(#ORB(&,'Z1`0Y1$NP@!A#FW#CL.WLT!VZY_(O]!]^@&KR5GG#6&1A
M@R[E?'.+QL:CI*O_`+^M\'5`FSL`1._)%_>GS('IV9'!.<$Q,)><-]N&X&IM
MN[;M?=MQ=-^Y'`:R!0YC*DRS1Q)R>>XS@#MMH#6G/?5V9,G'T;ONN[=4'6_+
MT#Y?HX'`P^`;?>AXCH!]:9D>D9%CON]`NE/O,24"\\I3K'$65@45``R7,ZAW
MSQ-,3E`1V,)1X:`W#KG\B_T'WZ`77/Y%_H/OT!JERR#3,<PSBS9!MM9I%;:$
M,9S.VN;C*]$H<I1-LI(2SQHW$X@`[%`PF'V!H`'I/U9O3MB7SJ/5[K<;R;AB
M;D=GJK:UW-DB?;P/)U.O34=P]NRHZ`]NK>J/Z?5T7^F@.[O"@N0X'0F[(:KK
MD-X<BB-G0AE$CB/``,`&$?9H`QJ5?JCD:NLK=0K76;M59+K!'62J3#*=A)`S
M58[5V5I)1J[EHL9JZ2.F<"J"8AP$H@`AH#:^N?R+_0??H#@RZFPB4$]_]X3`
M'CMXAOQT`V%;S=C*X9&R+B.KW6!F<DXD1KCC(]0:++'E:BA;F1Y&MJ2O]D&P
M?=&*9E"@D=02"'*<"B(:`=#KG\B_T'WZ`[%5,8P`(%V$?(??H#(T!##WX3\E
M+9R;UY9;_P!MK=5ARL&I]^B*TT+AY(.1\"]0Y>0GGL36D7^H3NK6K[K&W:E\
M]R[;L+.UEC8J+E5\T:J]5=6G'NP,DNE&FVT&@LU>JMEDED1RIQHU41!J,=XV
M_<IR-412++'*(M45P#IR)1#<&B2@B5,KD2\$PWV,/#??4`=+NE[MZ))<2-\R
M^<N>-*^!&HOPHM/BQ2B=B*7'K^NI92KXW.L%P1:5=G7A5OXM*U6H4$%B9.1J
M[PPQYR2E47YG315$R;D\(\YB'YTC\IBNHZ0(;\>D;8`UFKMWHQ;7>U)T@M7+
MKUDYJ21*VDBHJTK&VE7I[*$;WFXG6\Z.S^!U:?/0<69PPW5GF(NFI214=4H&
M8ECBEL4S9C&$^H:<XB``J\61Z0!ON'/OJ3]T]"K5^JZ>DMKY>CVVDQOFD>F5
MK,K&>%RTHCJK@U2F6FZ'.26-%=YDDE&_+S7E3F#)<\7G<M'EA?)),6*BJXD4
M%/87SHRASBQBR`(`N+9/B980%-)/8-]]8C[YZ.>=]KW9%"]FESO=Y+G)1'1H
MJY53VI3F2'I6N2,R0*]/.1$K3'V`G33-_!/@?,S*-5FBZ3QB<GQBU70.55NH
MD<.`'25*!@_+6'CY;[:^OPWNG2.BO[.Z9,VB4JC5HJ5[/$7_`)8+VPD9>O5Z
M21JB)2N/:6'J#,N+'2:A8'90^IFZS"2KH=@`>N^CFSA4=@X"(J&'7Z6^G.O7
M>X.GVAZ_/XI;S2[>9U5HOUD3'5]N.*&%^N0)#JEQID/Z*.1R>Y'8&W:O4^,Y
M#<1``\1'AXAQ_,..@*7GKO\`<!?LJ=PL9%T#[JGB;M#M,31%KDQ/SPS7N2M,
M<G?'K<RP<N\Q`5Z&;-4`-OR*(+\=S@&@+3W99W$1O=1VN89SDR52.^N-/8EL
M[5%4JPQ]TAC&A+=''$G`JC>?9+"`#L/3.4?;H`I-`-]D+$V+\M1J<-E''-"R
M/$H@N5O'7NI05K:-RNTNDZ.U3FV#X&AUB@!3"ER&$`XCH"@GZE/;SBK#'J-Y
M#PMC.K,:GCE>W8O485F.)RL(1I?8RNN9J.BC*F66;L.N_7,W3`0!L*G*38I0
MV`N[53L([*:A4&=*B.U?`PPC2/0CNE(XMI\P^?)MTBHE<R<I)1;F1D'CCEYU
M%%53*&,([FWXZ`JS>JI@!QZ6_=-B?-_978IS",-E>-F9A&JU:3D"0$';:F_8
M_?8P8A5RJTEJ;86,FV5/&.@5;I&!8I"@4Q!*!:D[(.XP.[+M5PSGU9BVBI:]
MU<%;/%M!4!G'VV&>NH*S(,P6_N)L#3$<JH@4PB8B*A0$1$-`#YZF/J+T_L#Q
M(TDD6+*VYHR$5^PQ70W3D46BIF:1?N%RM!D#"\;5&`,L3J`F`*NUSD03VYCG
M(!$CV#]B&3O4B<L^^'U';?:,HTZ:D5W6&<,R+Y_#5"6CVKE1-2?=UMJ=%C"T
M3ZAN9.-CV0$%^0H+.5C%-RF`LOTK%F-,;03>L8^Q[2*376*)$F<'4ZK!0,<D
M5,H$*!6T>P00'8`_48HG'VB(\=`!+WF^F#VO=YM0F&=DHM=H>4#LW/[7S%3(
M",B;;#R9@YVYIKZ)%LVM<,JL``X:O`.(DWZ9TC['`!A?1'KEKQ;VPY-[<,@M
MVS.^=M/<AE3&L^T:[@U,5ZI#VN/DX_?E,>)F6TT+IH<P<QD%0`>(#H"9+0#5
MYPR]4\!8?R7FF]."LZKC&F3EQEU%#=/KI1+-19O'('Y3_P#%RSSIM40V$3*K
M%#VZ`I@>GSW699PCZJY;GW"(RM5E>[*83A\K1T^/TQ6"6:46%RQ7)*`;<B$=
M$OG\2@U$1#E:+B0=AWV`O);_`!<NPC^K<0#X0$IA*("/L$1`=M`?1/\`67\]
M`9N@(9N[I)0W<U,&(`&YJS4PV.4JI!V8JAMR*`8G'\M:+_6O'Y_JKO(GR(D:
M:9IWA>G@QB=P,F.GD$B[#BF:M$\^;\X<C&$/69`K-O(L)2*7-TRA)0*)G+7G
M(<@$,ZACE5<)BD?8`4;K`4?U<O#A.'2;1-J:I96FEWD,\,[W-RW$&#6.3',[
M!?#2M<4+5URXOD61L5%5$7!?G0>FR9*?-+BK2*^Z;ED(2/:Q]HMR;5-O)RSE
MP@FY0CP!3J"5-N@H0%%C@)S*\`Y=3ONGJFD.ZI-D;,N+>5;"!K;B]:GC5<$H
MZB\:]_$MBQT+/I:ZGJ*KDS5:G)!XHQM)?857;R3/)M3I`#N,DU1<(O$RB!A2
M.)]C%W$OL$`WX;;;AJ:-$9?Z=MMNH:E.MTR=$\^"7]8SC\B%%U"2)MPBVZ(U
M:X40:W*,76WQ49R2<2L@DLQ*:&@XIB6/91C,P``-#R0I.$42&.`\XI)<Q_\`
M-J*NKV@;6O;1NKZD^:6W6)J0P0T2)C4;X64HN+4P=WE2T::Z;,C4PQXJN*]_
MW*1O9::I#]4HUCVK!'F,0$$BBJI\`[%%5TN)G*X[>WX2_AK5!UJM=/9=/N+>
M#[/-G1J-YY:\5P3L3D3KH,LLC<KUJF12:+#VX8IQOOMO^QZQX<`_Y0V\];Y.
MBO\`XWM?_K]E_#Q&,&O_`,T7O[5WSCCZE$I0-7>#W%0/:AVUY=SY/BF=.@5&
M0?0S`PEYYFUO"!&U.#0*8=U%Y2P.VY.4`$>GS#[-`1$L_3ZGKMZ-5WH%O9GD
MNXS++&;[Q9^2=(E4EG6=)@QK\QCU!,47'UO[>(6&*4VW3ZQRAL&X:`&#_3?]
MRP?3YB[2K`_43.DHCF/'+)RJ!#)E6(SA,A0S,A]B<Z#PK-\=,O$ASKB._L`M
M5:`6@*(/J]&*7U;[N<XE`I;+V\&,)S<@;?9JEX#L/'0%[%[(Q\:R5D'\A'L&
M""/67?O'K=JS02+Q%11VX.1N0I?,QBA[=]`5$_5OMLWZEW=UB#MD[-(T^9U<
M.P\\SMMUJIQ>T*"M-PD&!9-27N"`G@6<%5HF(2%TZ!8W544.F@54_*`@67NS
M3MQC>TWMHQ)V_P`?)EG%*#7OI9J=*0Z:<U9I5ZYF;+)()*[J)M%YE^L"!3;F
M!`I.;<V^@*6GJ072>[Q?52MF.EI%PI$-,RTSMHI;8A^JG&0$9.1];E!9I@/3
M2&0L#]\]/P$3"H`C^D-`7QJE58.B56N4FLQZ,57:E`PU9@V#4@((LXB!9(1\
M>V1(GRE(DFW;E#8/'Q]N@-@T`OXXZ`QD&;1LHNJW;((*NU`5=JHHI)JO%@33
M1*N[4(0#N%R(HE(!SB)@(4`WV#0&3^>VWX^'\_PT!"_ZE\R[[BLY]IGIM59T
MH=EEZ[,<W=Q@LUA`T5@3$LD6=^TO!(?=-O<[!'%0*54-E!0)[#CH"+'_`%%G
M;B:E9!P3W4T>/"%9V6(+B:S.XD#-?M=IHZ9YW&\H8Z0E(592`37:("7BF$>3
M8?A#0%BGL'[CFW==VEX5S5]0FO.6"I-XNZ)$4!11E?JL?]O7%%8"_H.O+L3N
M``W'IKDX<=`&0G^LOYZ`S=`0Y=U[YRV[FYDK=9=,P5VHF#Z<0`__`*!8/'Q\
M?9K2)ZQ+^>Q]5]X^%R*O_&:=X5Y?5.Q,CM@MM9-CQLE15?YTW#_$@]N*[3-,
M6S,TS?W,*WY4SE8D<!*2JJ:(;F3*P(#E!F40XB*QB[`&LD^DFZM4LK.*^U77
MEL]*R(CHHFHLCJJGA:F9.SL++U_2+>5RM9"Z21ZT3&B(O%%5?=V&G9CA+'3;
MZ[RE%1DQ)4>\)MI1P_09'<.X622212<C*L&H+F;MG@-2+H.>4$MSB41*(:C[
MKCMC<_3??\W4W2;:]O=CZPULZRPM5;EE<:N:B41OC^0J^W[JTO-'?H=_,D&J
MVZY6=BIPHG;AQ[#9*IE*:NGT\#56KV8>N`,7I)D/T4``HB=5ZX.!6[1%(.)Q
M4,'P[@&XB&KFV5U.NM_0MVYM5ES-=/:D<R^6YZ9$IC@J=B%.UO0[#2F*]7HY
M![K9,JUN'0JJ%V>UZ7B&"3=PT?M5&L1)N5OC.X;R39LY5;(JKJ&`IC"!>`;[
M:R"WAJB:!IL.V++6+BPUVWM8T6VDC1D.7+X7IXU6KT2J]O$M;3([>XN?.6V\
MQJNP5.[EWT(WLRSDZJHZ3DI%RY$Y1$BZ;PKMNL!!V-TWB0J-U0$!\`'<=:J^
MO&K:Y>:O)::Q.V=6NS(YGPU143CVXDZ[<M[>),T4"QKY:I7\!,5A\PGQ5C@P
M^(TBL[__`!#7QUO(Z-?^.[8_Z_8_P\1C/K_\SWO[5WYPXW\>S8/Q'?V:DTI9
M`!ZGBMU[SN[KMO\`3BQ!9(J#&O)*]RN<)V9AU[)6X%O6DE%L>Q-J@&LA&'E6
MSAP0ZHLSKI$7%Z@`G#PT`:(80]40B0()=\_;Z1$J12$1)V>@*12$3Y>@"),I
M`7Z8"%`A0X"!`VWWT!51L\7D/TH?5,K<_<)N.FDH*[1%ZG9VKU]>JUVWXNRN
M*Y;N,17_`*V33BHYF20?H%;?4*E159%$!#;;0%]".D8^88,I6*=H/XV39,Y.
M/>-C@H@[CY%`CIB[14#@HBY;J%.0P<!`=`9F@*&WK$LFTEZL61(QZ@#EC)S&
M!(U\W,82E79OJ[5VKA$QB[*%*JDJ)1$AB'+ON`@(:`F1]2;T7L6R6!;'?NT&
M"M5/R+CN-5L3O&+6\WFPU;)]>8ME%)J(:PUBGY5-E;&K0IUH]1`Z::RB8HG)
M\8'`!D/]/SWTUIFS>=D5^9P5=F5W$C8L+V1&+80KBU"0SAW8<>3[E!%%21L4
M,8JCF,.X,991J"C?<112`P%JDHAS%-S`8-RCN`[AMP$./Y:`_/M[H6KKM?\`
M5VNUBM#=9O'T_NX@,LIJ/"&!-W4K!;XF]$DP,4-SMU(F4-L(</[9@WW*.@/T
M"FSUI)-6LBP<IO&+]LW>LG2)@.BY:.DB+MET3AP.DL@H4Q1]I1`=`?;0"T!P
M4>;<0`=@]OL]FW]=^'Y:`P):6C(&+DYR:>(1T/"QSV6EG[HX)-V49&M57K]Z
MNH;@1NV:H'.8P\``HZ`K7=E='[O.\W-O<GZD>%LT8_PHQRI<YG#&,$\E8@7R
MP\7POCIVQ;Q:E>`UKK#:OM';]L0KGD(J+ARBJ(B'AH`@.]WL;]0?N'[;,BTC
M)7=;A#)T/#1B]^B:9!=L9Z?8)FTTAHXG82/@;.CD*64A)"1,V.U!4&RW.5<2
M"`%,.X`*?Z</N;^@L&9>TRP/C)-9YJ&9L;M'1SI&;2<85K"Y$A4$52E`'#AH
M9@^,0G`!07/L&X[`6SDAW,0>(;CX#P$!\!`?Q`>&@,[0$*O?&F_ANX-Q)&3,
MBC*5.M+LG!AY$EDFP.6#CX@]J3A(0$/QUHV]?UM=Z5UZEUB5OEVUW86;(I$2
MBJZ.-4<F;G3LY&4'2:2VN]K1V"Y5E9-*KDYT545#3\;7V.AQ2?OR%=JI*%!E
M'+&,FV67`Y0!>5Z`%7%DV/L<J)?_`#Q``'8-]6)T:ZE6&WKAMUKKT?>6N+6N
MQ3-P153FW'AAC3$J^XM%2X1[+1%;;4XI\5>Y>7/D&+7<P/4(28GG<D5U-V)9
M*,9&,H``WC67]V3=-VY!!!!#J&302`H!R;&'_+K./;G6>>#;]YK.HWRS:C?-
M:R%BK5D<>9'>!BURK1$3CPY$07&VLTS&(UR,CKC7Q*O*JTQ[3=I?*\<G+(PZ
MJB+>(L%4C&KP2II()-I*3CDUD9,_3*7BDZ.3G-Q$"[C[-27?=84AU--,;<QL
MLKS1(Y)'M1&R)*YL:JK'I\*55>2^TIUOH=X])'O5[WQ/\.9:X56J+[4X@R77
M*)'T>>'GG!SO8XZK9I*J""[QCT-^M'O3&`QGT<H?X=C")T3`!R[APUAYOCJV
MRYTN?;NN*DCHZMM[BOUM$JB)*ZBYZ)P^$OG2-MW;(67,*(UKN*4Y\U`DL\RO
M*KN4DQZI1%0030/SAS&*(@)`*!2&'GV````W`=8&ZUJFHZGJ:6ELZ2:625L;
M6KBCW*]/@[Z([M);T^R1-.>]^9LT4:N55X43!</>A8+QE'.8?'-"BGB8I.X^
MGUQHZ2'B9-PC$M2+)F_WDS\!_+7Z3^E]B[3>G&@:1,UT<L.C6T:M=BYN2&-M
M%X8X8\##;5Y([C5[N^C6K72NI\IX^:LRX[[?<96S+>5;&PJ]*I\4ZDY)\_<H
MH'=F21.9M$1B*JB9Y"7EW'*W:MT^91590H`'B(7X4TA+]$0X=PUH[R>_FWO&
MKW)F;,OKTQC'"Y1<R-'H%=:L9>-@3H&$RS)JY2=LD2`.R:A([<O`=]`6!1#?
MQ$0`-]P`1`!X<-]O^Z/$/Q#0%8S_`%)&#(5]CS`O<8@HQ;6.N6>1Q)-HJN4&
MC^9KEH9OK#$J(HF$BKU.ORL6X$Q2E,"9'IA'APT`9GHG=ZU2[@^UFE8=L5K9
M!F_!L4G2)FMRK])*PV"E1`E2IUKCF[DY5Y9G]D%-DX.D!N@X;;'`H'+N!-1X
M%$QA^$@")C&**0%#;?<X*<O)PXCN/\]`4%_5ENU6G/51R;:(:>B9:`@KCA5C
M*S$8\1>L&CFKQ%63L")G""JB!U8A5!4KC8P%2%,0,.X#H"^E7YR&L\)%6*O2
ML=.04RS92D3,Q#M%]'/F+M!-=H[:.D%%D%D5TE>8IBCL8I@X:`I<>M!V1S_9
MSW"07=U@@C^K8UR/<F]E;2M<*=LIB;.;)T,SLSZ'+]-&VMRD9^P`VR?U`+M]
MA+TRB!8M]-/U$*!WPX8KRTC-P,-G^LL48O*^/#O6K.0-+M$^F>W5Z/7<%<OZ
MK9`*#A,Z13BT55,@H!1(&@`K];3TQ;%W3PD5W&8'KYIG-U"A#5ZV4ML9%O(9
M1H3<YG30D3NJB5Q:ZDHJJ=HW,=,7C=0Z1#=0J8&`\'T??5&JMLH]=[.^YN>#
M'^>L7II4>ER%Z%Q!?O\`@8@@L8F`DUY5-H6*O]<22*S.T<BB=\@B0Z7,ISET
M!8CV'8!`-P$`$!#B40$-P$!#<!`0T`V66\Q8QP129C(V8+O7\?4J#;BJ^G+$
M](T3,?\`R-6#81,\E9!<1Y$FS9-5=4_`I!T!#KZ;W=%:._WO9[I>Y-@>PPF"
M,38_JN#<+TUZZ=-&YPL4^]M,W<9Z'27,P4M<^WA$E1Y@449M%4T0,`]3<#MZ
MZG>7!X7[:I+MRJ-K8MLS]PY$*FNR9/D_N=.Q@\<IA;;/+E07!6*92R"01Z!E
MBE*L59<2[\@B`$J/:EABK]O?;=A3#M,5:.J_1,>UZ)1DH\456<Y(K,4I";L)
M7"']MP:>F72[KG`3`;J[[Z`(0`YA`.4#B7P`=^`"(".^W@41#CH"A!W!OR>F
MSZO%DNM",FXK>/<R1N1D8:$=)J[XZR:S)+6ZCK(H*EZ#I*)GGS4J!@#XDT>'
M'0%Y_$^5\>9NI%>R7BNV0UUI%G9-Y&'G(-V@Z0.BND"AF[U--4R["1:*"9)P
MW6*FLBL4Q#D*8!T`Y^@!Q[A<`5_.L$BS=KC$6:%%1Q7+`FF"HLU5D]EF;Y'@
M+J+=F*7J)[@8HASD$#!K'#U%>G;;7J"VXW2]35L.M6E7V\J<<RI@UZ\4;WI7
MV%T[5W9<;<OZQYEA7XD3GWIWD6DKVA]PE9DSHLJHE84T5E2HO:[)LG+5PCX%
M6,#URU=-SG`?B(H03;^W6I/7_1=Z@-NWDNG6.E-OF>9A+!(KZQI7%:L;W85,
MA[+J3M*X3+<2OBB5E?&W+XL.]:\SWFV$>Y4H-BK8RGP3:I%013(]B0!)$`'G
M*4`?[?WC<3:^RV].GJ=LUC9%H%\ZWB;1$7V=E5*;)NG9KIE>EW#E53/E<.=R
MLATS?]-9\QTV#-D',O$@'_#MP1$W_,O`H^'GJK:KT2]4]VZ&6WV_?I+';1Q*
MJX?"B(M,5PPP/.+<FRV)*CKN'QKA])J4EVZ=R,TX.*N.9D%5N453K/85+G/R
ME(*IN:2^'FY>(ZM:_P#2YZD-;U)SI-MWJ)-@Y\BY6-IPI3,M>W!"M0;WV59P
M(]+I'4;2B8\/>@2G;_V124'8(VY995CQ4BUT9*+IS!V,@0T@ARF;N;"^(`-%
MDFBVRA&R/,F8P!SF,`"`Y;^G+T':KMS7;??'5B=KKRT7-;VC%5[$D145KY%7
M+16HBI3*O'CVQYN[JJR\M)-.T%7M\Q,KG*F7P\T2BJN.&/(DR+S`&VP#^8\>
M/CN(``"/]/Y:VDI'&J^8K<KU:B*B<$1.2$%O1ZN:C?T:_%]W,`/,OID=HW<1
M>YG(&;:E>LBRTW(!(GBY_+N33U"*<E03;@-?IS2RMZ_`("DD'PMT2<1$1XCO
MKL=S3ZAZ1G8_C6RL;5C"BW[&<S'R$7)=:B9HRK7&TBM$/47S-O-,F5K(A,L"
MKH`!T7`'3.F<Q-MC"&@)+3[FWX%'?F$0$.`CRCL'D'Q;;_AH",NW^D-V/Y$G
M5['DJF9'R1)JO9*0)^^<WY8L+-FO*.E7;E&-8O;49I&M2G5$J9$2)E3(`$`.
M4`T!X(>BOZ=39XUE(+"\[49ED?J-)JI97RA7YAF?80$[.386LKQL8V^PB0Y3
M;>W0!%Y([%<&99QQCC%5X>9>D*=BZ,=Q,"W9YMR;$RTNT>I((+A=IV,L;:3O
M"I4D"E3/)*+G(&_'CH`<$/1-]-1NB*7_`.=DW)S`83N760LCK.S**;]50RQK
M3LHHMO\`$)@V'CH!\L`^G5VQ]K]SCKOA&)R)4'48TDF;>MGRYD69HAD95O\`
M2N/J*1,3[^O.5$4Q$R!S(\R"GQ$V-H`C<VX5QIW&8NM6'<MUI"UT*XM46DY#
M.%7#)<HMW"3UD\8R+0R3Z)EF3I`BS==`Y%4CE#B''0$?[#T4O3EB@;+Q6$)B
M*F&B@*-+'$Y6RA%V-H<`X';2\?:FJZ)B^'P[;AX[CH"17%6,*WAR@U[&U1<6
M-[7*RW=-HUQ<;5/76PBDY=N'HE?66RNY&;E#)JN3%3,X6,9)+8I1V*`:`&[N
M4]//M#[LUCR.:\+UB<LXE(5.^0HNZG?4S)`'0.:T5T[!\\%$X`)/JOJ0+ML`
M:`8FO>ES'T)D6"Q=WO=^>/*BB4J3.JQF<6LS&,&Y"B";=@I8ZM*.V:")1`J9
M2'#D*7AH#S'7HW=I-PF6EBSI.=P?<M.LSF41>YPSI=+*U3.8=Q%M&1CB$8L@
M'R1(30!=4'LR[<<18NOF',.8X:8CHV2T'*=N1QS-6"MS[YTYCRQ1I5&U(R:E
M@93"$>4$TG*2Y54P\!WT`*CGT7?3LDUG,A8\+SEMG'QA4?V*UY8RG8+`^4'A
MSO9>0MJCMV8I>`"<1V`-M`$]VW=E>#.TYW,KX8;Y`BF4U"LH)2OV/*=]NU7B
MV+!XH]0)7ZY:IN3B8%?J'Y3*M4TCG3`"#\(`&@'5S;A2G9_HCG'5Z>W)A7W<
ME&2JZM#NUDQ]/*.(M8ZJ*'[DJ;^,F4V"X'$JZ!5@36+P,&@`&2]%3TXA7=/)
M/!<A89%XL9V[E;%D[)DM*/'2H[JKNWZ]J!PX<'$`W.H8XFVT`YF%_2Y[/NWO
M(4!D?"]3OF/IJ#E0F$XR#S!DQ*J2+P&SAKM/U):QKP-B:\C@1Z3M)0G.`&VY
MBAH"1G0&&MOSB(;^`>6WAKCS&M7*]Z-3LY_*>3DJJTP<?#EV#SWX[B(B;_Q"
M.^N'/6F5F=S>VM/OG,:3(O[RJ+#W]OW5%M_'\#KIF?V/_*^@]:6O]PY`!#V@
M/YAO_B&O2CNQ_P"5]`_=>QAP)!$>;<H#MX@F7?A^([CHB(^K%61')RS+0ZJM
MO7!F9?O'!0$#>T0V'B)A'<=_(V^W\M>+6K'*K,C4;3CF55]Z43YSA'YEIY>7
MO_`?37N=AI<Z7A]CC%-ON<9(L8R2A6*:D<M(,#2;=P^773;M6`,BN6IE57JR
MH$+\0\HCOL.@,K#!+J;&=5?Y"E'$M;YED,Y+JKMF[0&1Y<XO6T2@V;)ID1;Q
MK50B12CN<-AW$1T!OLV6:&&E@KH,_O\`]M>_9?N7/]O"4!NI]$+T$_[AFP.>
M7G`..WX:`U['@7X*?#_]3OL0W?IKC-_MH%0AP.+E7Z4&P*B)@,#7DY]AY1-X
M:`W7E';?8=O/8=OZZ`6PCP`.(\`_/0&IU2\U2\#/A5)A*9_;$VXKDX=LBY*B
MRFFA2G=,066133<*-P.`'%,3%*([;Z`VL0$=R@(%,("`&,&X%$0X&$-PW`!X
M[;AOH`4NW*YY`R/9<L6*QV-&8J%?LKFDTM*-B$8>,>A%.UU)*9!L19TLHX,4
MR*?.940V$0VX:`*W0"_C^/Z:`0\-]^&WCO[/S\M`<\IN'PCQXAP'C^7GH#CP
M'8>`^7M]GL_GH#GE-OML._CML.^WGH!<H\>`\/'@/#\_+0'&@$`;\`XC^''_
M`+-`+0'=/]9?ST!FZ`Q%OU_R#0'RT`M`+0"T`M`+^./A_/0`,=RCF>R9E7&.
M":F1NZ!BZ)D6Z"ZZBD9&L6"HDAU)HB8?WFB)Q,L#<=A74$A/`VX`;!BZ+LS;
MN7O;1E>;;;ZO7Z/&M;BO87XN8UO?I9XDZ;QD0S;I)1D:$?%(=3Z=$FR":@%,
M(FW'0&/W12%TEYBDXLJ-ID(F<R%,LVL2PKCQPQ>QT:P4^HLMHL;U$W65BV38
MA2-FR8IE$_.H<3;```/?E_(2>%<2R5J535FI"&8L(J&1>J_WIV?=`DPC2NSC
ML=0RZXBHIO\`%L`\-`"Y=E+QC2$PE9I2U3\WFO(&2*X66;FD701"D/)IF4G*
MHQK::I(QK"L&KI!$!(D90JH`<3^.@"@[@KH^QWB:X6R+EDX:0BF!P8.%&B3]
M=R_=BHU8LV:+A5-(CIRZ53^,W-RE`1`HCMH`%I6CS6#L:X#GJQ/69EEBZ7Z$
M5G(]"8?&C)]S:0^Z2C%_7U%/H5SI-ED$E%`2YR<1,/D`=.?KP7&N(KK:@4%.
M32BEHZ'('$3S4P0\?')H["!U#I+.1.`!\0]/AOH`()G'=SQUVCH34C:+-5[$
MP9Q;RL5:L2:T20D]9)M!47EB,W(5S-6&8%X(&2.8$FJ8E(4@G`YA`/DUJ2Q]
MBN.M60W:B:L)4X=Q85P*55T]F18-4EF;5(!#ZF1D)$W23('ZU3>/'0`M9MMM
M_+3(5JO/3%4R9EJ2CX#'>/*T\!M^W6$LY23<O;4X2(JO,/FT:MLX,8Z;=%<_
M31`1*)M`%2PK3JCXS85J)G/I7U>KJ+3]S3?U$NJF9FVZDI,//J5NJ_7*0BZI
M`4,(<PAOP#;0`.8%K60LY0^57[G).0Z_CFP6Y]^VIA.=6<V:05C.NT;"S?+I
MI`QB&G4*=R1N5,KA;IIAL5+<P!EVH7&.<2+&/;7*"=0KK8LO<9;D>3R\=%MB
M_<'+85`^G4L,F!>FV.H4Z9%U2F,4W(`"!'8UFLAQ';A.7&WV^^-%\D6QR3$U
M8:V.4-9Y>3G%44(Y_)2@'^XJ0L>R3%1-H@9)-=4O.8`ZA"@`Z"L3E*1N';WC
M61R!;"Y*8,X^UWM*-FG80M3H\,@B0C.<;$$Z,Y9IXY>1=P[.<3'X)E$OQ:`.
M3(E_C<?P02KEJM)R<E(-(2KUYF<A']CLDDJ"45$,Q-\*8+G'G45'X442F.;P
MV$`1,R_O>QV3'>("WZ=3R1D.5;RERCJ?(&B:Q3<>,C*NY5JBU03*\<JJD2,5
M!VX5%PN=(3`!2F*30!W-&B+%LU9MQ,*#-LDS0ZAU%5A11(FDF95=0QE%E132
M+SF.(B8P;[Z`S$_UE_/0&;H#$6_7_(-`?+0"T`M`+0"T`O'A_CM_M]F@!E-A
M6]L<LWS(=6O\1#L<CLHEE*"_KJDG9H-&)2(W!O7'1GR,:F54J8B4RR2G(;8W
M((AH![:728&@098"OMU46PN7#Y\\=+F=2<Q).U`5>RTP_4`%7LB^.&ZIS<-O
MA#8H!H!FE\$RTQFZ>RG.7$RL')PT5`1E<8,3M)-A%-`14<Q@30N-VC"4>)F.
MX^E*19PD<2"<"B8!`<#,6-6F6*6M4UGI(Y9"5B)V+>G2^H;-Y6"=`\:"X0$2
M"NS7$ATU2E-U"@;F\=`>!#XC>2.1&F4LC2K">LD`R4C:=!0S1=K5:BW6$PNG
M[1-ZLN]?S+WF'=PIT^0O`I=MM@&;[F$GN3\AXFP'".TFYWSQ?(MI642!RU9Q
M5;*885-^U`Q150=/RG'81X@4/PT`]L=C"0F+U$9%R+*1DW+U1FNRI4#"L'32
MLUA1X4I'\PF$@LN[D9QVF0"%6-TRHIARD+[=`9N5L7?]4G./T)&8(UK-3M[:
MW3D`9D+G]SJ121QBV"BH+IE;-D'*@G.(E/S"`!H#R&&,+9-6$S_*5SC[E7X.
MV+6NE5YE7DX5%@LF!AARV$_55^[JP!%S"V+RE)U3=0X"8I0`#MGK%TYERJPL
M)`61"KO8>XPMI3<R#!648NS0O55;HNFB*[83E(Y,10A3&Y14)Q#0#9/>VJ=E
MLLPF39/)#R3<,ZZYAY=<T21":7=O072<N*TLFX&-K#063D4$#I)J+-R"<Q3&
M.(&`!^<BU"3N&.YVC5V:&L.9J%^Q(32B"K\\<R.*+9V8I3K(+'6.Q!1,IS&Y
MA,;F'?CH#U*#38C'M/K]+@2"E%5V,;1R!.F!#JJI@)W+U?Q$5G[@YEC#OXF_
M#0&F9HQ6KF"%@JHXL`P]82LD9-6^.2:'<+V>+BE1<(P0+%72^F05=<IS\#<W
M*'#0&)+8>2G<K4R^RTJ@M5\>P)V=+HY(XJ+*+GE@*D:>4=`<R"BK5B0J:!`3
M`$N4O$!`-P-<IF")2&R?D#)-GN'WHUOGV$FTCF+):,=-V,/U0@XB6?BLHX<1
ML84Q3`T2Z;=95(AS\VVP@>GF/$UKO]GQ?:ZK<VU1>X\F9.2*+V'"?3<_=FR3
M51PW8"X;M?J4D.H0@K#R%`V_LX@:95NVAW#9<M61I"^/I..LS.(9KHG:F)9W
MI8X[1XX:OK'U`!O'2D@U*=9!FFB"B`%3`Q2@.X!8CQXZ`[I_K+^>@,W0'Q/T
MN;XQ$!V#S_P#0'39#S'YO=H!;(>8_-[M`+9#S'YO=H!;(>8_-[M`+9#S'YO=
MH!;(>8_-[M`+9#S'YO=H!;(>8_-[M`+9#S'YO=H!;(>8_-[M`=%`;BF8!,<H
M#P`Q.;G*80'E,38HCS@/AP'CH`4JC$802SA)K0UHR6ZS`2.(>;:S;?(!16@.
MLWZ23TTS76\0$%U>GR=-0B/D.@"P$$/,?Y<WNT`MD/,?F]V@%LAYC\WNT`MD
M/,?F]V@%LAYC\WNT`MD/,?F]V@%LAYC\WNT`MD/,?F]V@%LAYC\WNT`MD/,?
JF]V@%LAYC\WNT`MD/,?F]V@%LAYC\WNT!V*"/,'*([[\/U>[0'WT!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
